Latanoprost Elvim (Latanoprost)

Latanoprost is a prostaglandin analog used to manage conditions that involve elevated intraocular pressure.

• Open-angle glaucoma: reduces intraocular pressure to help prevent optic nerve damage.
• Ocular hypertension: lowers eye pressure in patients with elevated pressure but no optic nerve damage.
• Other forms of glaucoma: provides pressure‑lowering effect in secondary or pigmentary glaucoma when appropriate.

• Latanoprost is a synthetic analogue of prostaglandin F₂α that binds to FP receptors in the ciliary body. Activation of these receptors remodels the extracellular matrix, enhancing uveoscleral outflow of aqueous humor. The increased outflow reduces intraocular pressure, thereby decreasing the risk of glaucomatous optic neuropathy. Its selective receptor activity provides a sustained pressure‑lowering effect after once‑daily ocular administration in patients generally.

Latanoprost may cause ocular and systemic reactions, most of which are mild and transient.

Common Side Effects

• Eye redness: transient hyperemia of the conjunctiva.
• Eye irritation or burning sensation after instillation.
• Increased pigmentation of the iris, leading to a gradual darkening.
• Growth of eyelashes (hypertrichosis) on the treated eye.

Serious or Rare Side Effects

• Severe allergic reaction with swelling, itching, or rash around the eye.
• Persistent eye pain with vision loss indicating possible corneal ulcer.
• Inflammation of the anterior chamber (uveitis) that requires medical attention.

When prescribing Latanoprost, clinicians should consider several safety measures to minimize risks.

• Monitor intraocular pressure: assess response after initiation and adjust therapy as needed.
• Evaluate for ocular infections: avoid use in active conjunctivitis or keratitis.
• Assess hypersensitivity: discontinue if patient develops allergic signs.
• Caution in pregnancy and lactation: safety category is unknown; use only if benefit outweighs risk.
• Inform patients about possible iris color change and eyelash growth.
• Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents, affecting efficacy or safety.

Major Interactions (Avoid)

• Concurrent use of other prostaglandin analog eye drops: may increase risk of ocular irritation.
• Use with non‑steroidal anti‑inflammatory eye drops: can reduce Latanoprost’s pressure‑lowering effect.

Moderate Interactions (Monitor Closely)

• Beta‑blocker eye drops: additive intraocular pressure reduction may cause hypotony.
• Alpha‑agonist eye drops: may increase ocular surface irritation.
• Systemic carbonic anhydrase inhibitors: potential for enhanced IOP‑lowering effect.
• Anticholinergic agents: may affect tear production, increasing discomfort.